image credit- shutterstock
As part of Abu Dhabi’s efforts to expand its oncology research capabilities and address unmet treatment needs for patients with some of the most complex cancers, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers.
Announced on the sidelines of the Abu Dhabi Future Health Summit (ADFHS) 2026, the proposed collaboration will strengthen research and clinical expertise in CNS oncology, including brain tumours, rare conditions and paediatric cancers, further cementing the Emirate’s position as a leading destination for advanced and personalised oncology care.
NeOnc’s investigational pipeline includes NEO100, an intranasally administered perillyl alcohol therapy, and NEO212, an oral perillyl alcohol–temozolomide conjugate.
Two children in Abu Dhabi are currently receiving investigational NEO100 through NeOnc’s Compassionate Care programme. Building on that experience and on the Company’s existing DoH clearances, NeOnc is working to open a Phase 1 study of NEO100 in the Emirate.
